Anti-inflammatory drug approved for use after cataract surgery

Article

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

A non-steroidal anti-inflammatory drug (NSAID), for the treatment of postoperative ocular inflammation following cataract extraction, has been approved for use in the European market by the European Commission.

Yellox, owned by CROMA, is to be administered twice daily as an ocular NSAID in adult patients after undergoing cataract surgery. Otherwise known as, Yellox (bromfenac sodium) targets the COX-2 enzyme- one of the prime causes of prostaglandin production and ocular inflammation. The solution penetrates through the cornea and ocular tissues to treat ocular inflammation.

CROMA will collaborate with Bausch+Lomb to promote the ophthalmic solution in Austria, France, Spain, Poland and Romania. Bausch+Lomb will manage promotions in the remaining EU countries.

Chief Medical Officer of Bausch+Lomb, Dr Cal Roberts, said: “Yellox is very promising for cataract surgery patients. The drug helps meet the unmet needs of both patients and physicians alike across a number of European markets, offering them a new choice to treat post-operative ocular inflammation following cataract extraction.”

Recent Videos
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
Related Content
© 2024 MJH Life Sciences

All rights reserved.